idea-010 · business case

Who pays, from which budget, how much, and 2-4 commercial routes to first revenue — every figure below traces to a copied claim or a declared assumption, and the routes are laid out unranked. Choosing a commercial strategy is a Tier 3 act, so this page presents options and stops.

Single-use strip and handheld meter measuring potassium and creatinine from a fingerstick drop, with on-strip hemolysis rejection, for RAASi dose titration in outpatient heart-failure and CKD clinics — business case

Intended use: For the quantitative measurement of potassium and creatinine in fingerstick capillary whole blood by trained healthcare personnel at the point of care in outpatient clinics, as an aid in monitoring adults with chronic heart failure or chronic kidney disease during initiation and dose titration of renin-angiotensin-aldosterone system inhibitors; not for use in emergency, critical-care, or dialysis-adequacy decision-making.

Who pays

The budget-holder chain has one cheque in it as the file describes the product, and no claim in the file names who actually writes it.

Writes the cheque (for the device): the outpatient heart-failure or nephrology clinic, buying the meter and strips directly, out of its own point-of-care testing/supplies budget — this is not established by any claim in the file; it is this case's own assumption [assumption A1], because nothing else in the candidate names a distributor, a GPO, or a health-system central lab as the purchaser instead.
Writes the cheque (for the test): Medicare or a commercial/Medicaid payer, per test, through the Clinical Laboratory Fee Schedule rather than the Physician Fee Schedule — the file's own load-bearing negative economic claim [claim 14: unconfirmed]. Whether an existing code even fits turns on CPT descriptor text this pipeline can never resolve (AMA-licensed) [claim 11: unconfirmed], [claim 12: unconfirmed].
Out of which budget line: the clinic's point-of-care equipment and consumables budget for the device and strips, meant to be recovered against the CLFS payment per test — an inequality with both sides unquantified [claim 14: unconfirmed], and dependent on the clinic actually keeping that payment for itself [claim 37: unverified] and on both analytes remaining separately payable on one strip [claim 38: unverified].
Against which comparator: sending the sample to an outside reference laboratory and waiting a day for the result — the status quo the candidate's intended_use: is written against, and the reason the monitoring cadence in [claim 21: unconfirmed] currently produces a delayed dose decision rather than an in-visit one.
Stops buying instead: the outside-lab send-out draw for potassium and creatinine at that visit — but only if the in-visit fingerstick genuinely replaces that draw rather than adding a second stick on top of it, which is itself an unresolved, deck-surfaced proposition [claim 33: unverified]. If that proposition is false, this device is additive spend at every clinic that adopts it, not substitution spend, and the whole budget-line argument above changes shape.

The chain's weakest link is its first one. No claim anywhere in the file says who buys the device, and the second link — whether the clinic is even paid enough to cover what it spent — is the file's own honest negative [claim 14: unconfirmed].

The money model

Decomposed, not asserted. Every line resolves to a copied claim or a declared assumption.

Line	Figure	Backing
Addressable volume — annual Medicare Part B claims for CPT 84132 (potassium) and 82565 (creatinine), all settings	not established — blocked by a missing procedure-volume cache, and even once resolved this is a Medicare-FFS floor, not a market size, and counts overwhelmingly central-lab draws this device cannot take	[claim 16: unconfirmed]
CLFS payment per test, potassium (84132) and creatinine (82565)	not established — blocked by a missing payment-rate cache; the cache that exists is a HCPCS/PFS file and may not carry Clinical Laboratory Fee Schedule rates at all	[claim 14: unconfirmed]
Realistic net price per strip to the clinic, bounded above by the CLFS allowable and below by strip cost-of-goods	no price is asserted, because the bound it would rest on is itself unverified at both ends	[claim 17: unconfirmed]
Net per-test strip price the manufacturer could actually set	not established anywhere in the file	[assumption A2]
Manufacturer gross margin on the strip at that price	not established	[assumption A3]
Meter price or placement cost to the clinic	not established	[assumption A4]
Potassium and creatinine separately payable as two tests from one strip, rather than bundled into one payment	asserted as a proposition to be checked, not established	[claim 38: unverified]
Clinic captures the CLFS payment itself, rather than the payment remaining with the outside reference laboratory it sends to today	asserted as a proposition to be checked, not established	[claim 37: unverified]
Payment per test exceeds the fully-loaded cost of performing it in office (strip, meter amortization, QC material, operator time)	asserted as a proposition to be checked, not established	[claim 36: unverified]
Addressable share — outpatient HF/nephrology clinics insourcing testing within five years	10-20% of clinics, over an uncounted denominator, the Generator's own assumption	[claim 18: unconfirmed]
Titration-visit test volume generated per insourcing clinic per year	not established — the qualitative monitoring cadence in the file (baseline, ~2 weeks, ~1 month, periodically) was never turned into an annual test count	[assumption A5]
Share of insourcing clinics that select this device over an already-cleared incumbent analyzer in the room	not established	[assumption A6]
A published capillary-versus-venous performance and invalid-result-rate figure that would make any of the above buyable at all	does not exist; the mechanism claim is unresolved and no connector reaches it	[claim 22: unconfirmed], [claim 23: unconfirmed]

No composite dollar figure is asserted anywhere in this table, deliberately. Every row above either the connector could check and could not (missing cache), or the candidate itself declined to assert a number, or this case is introducing a new gap as an assumption. Chaining them into one line would manufacture a market size no claim in the file, and no connector run for this case, supports.

The two connectors that would ordinarily carry a business case both refuse, run today rather than assumed from the candidate's own Verifier pass, and the verdicts go on the page:

python3 -m connectors market "the addressable market for a fingerstick potassium/creatinine strip in outpatient HF/CKD clinics is X" → unverifiable — "Market-size claim (...) has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand."
python3 -m connectors adoption "outpatient HF/nephrology prescribers will change a RAASi/MRA dose in-visit on a point-of-care potassium result rather than ordering a confirmatory venous draw" → unverifiable — "Adoption/preference claim (...) asserts what clinicians, payers, or patients would do. No free, authoritative, machine-queryable source answers that... Do NOT substitute a model's own estimate of stakeholder behaviour: a synthetic stakeholder opinion is a fabricated claim."

The checkable primitives hiding under those two unfalsifiable questions were also re-run for this case rather than only quoted from the candidate, and reproduce the same missing-cache state: payment 84132, payment 82565, coverage 84132, procedures 84132, hcpcs 84132 and hcpcs 82565 each returned unconfirmed with "No local cache at data/…" — nothing was searched, which is a missing input, not a negative finding, exactly as the candidate's own Verifier pass recorded.

Path to first revenue

First dollar comes from: the first outpatient HF or nephrology clinic that buys the meter and strips directly [assumption A1] — a device sale, not a reimbursement event. The clinic's own CLFS payment arrives later and only sets the ceiling on what it could ever have paid [claim 14: unconfirmed].
What must exist first, each attributed:
- 510(k) clearance for the creatinine channel, anchored on K070068, whose IFU covers capillary whole blood at point-of-care use by health care professionals [claim 5: verified]; product codes CEM and CGL both sit under Class II regulations [claim 3: verified], [claim 4: verified], [claim 2: verified], [claim 1: verified].
- A predicate argument for the potassium channel — a complete, two-product-code, 30-year sweep of 21 CFR 862.1600 located no strip-based fingerstick potassium meter, a bounded null rather than a clear field [claim 7: unconfirmed].
- A Dual 510(k) and CLIA Waiver by Application pathway that exists as named — structurally unconfirmable in this pipeline, no connector reads FDA guidance [claim 8: unconfirmed].
- A hemolysis-detection-and-suppression channel that reliably tells a materially biased sample from a clean one — the mechanism claim no connector in this repo can reach [claim 22: unconfirmed] — holding across the hematocrit range of HF/CKD patients [claim 41: unverified] and across a commercially viable shelf life [claim 42: unverified], without an unusably high invalid-result rate in ordinary clinic hands [claim 23: unconfirmed].
- A confirmed CLFS allowable exceeding strip cost-of-goods [claim 14: unconfirmed], with both analytes separately payable [claim 38: unverified] and the clinic keeping the payment [claim 37: unverified].
- An FTO position — zero patents have been searched, on the rubric's one automatic-kill factor, in art that is dense and actively practiced by the named incumbents [claim 25: unconfirmed].
Calendar to first dollar: not established — the candidate asserts no month figure because any figure supplied would be invented [claim 26: unconfirmed], [assumption A7].
Capital to first dollar: not established, same reasoning [claim 26: unconfirmed], [assumption A8].
Lag from a clinic's first purchase to its first paid CLFS claim — payer enrollment, claims cycle — not established [assumption A9].

Routes

Four, laid out and not ranked. Choosing a commercial strategy is a Tier 3 act — the same class of decision as choosing what to shortlist — so this section presents options and stops.

Route A — Sell direct to clinics, billed through the existing CLFS codes

The model the candidate file itself describes: a device company selling strips and a meter directly to outpatient HF/nephrology clinics, which bill 84132 and 82565 to the payer themselves [claim 14: unconfirmed].

Requires: 510(k) clearance for both channels [claim 1: verified], [claim 2: verified], [claim 3: verified], [claim 4: verified], [claim 5: verified], against a potassium-channel predicate argument that is unresolved rather than absent [claim 7: unconfirmed]; a Dual 510(k)/CLIA Waiver pathway confirmed to exist as named [claim 8: unconfirmed]; a CLFS allowable that clears strip cost-of-goods [claim 14: unconfirmed], with both analytes separately payable [claim 38: unverified] and the clinic keeping the payment [claim 37: unverified]; and a purchaser identified at all [assumption A1].
Costs: calendar [assumption A7] and capital [assumption A8] to first dollar, strip price and margin [assumption A2], [assumption A3], meter price or placement [assumption A4], and the claims-cycle lag before any cash arrives [assumption A9].
Killed by: the CLFS allowable for 84132 and 82565, once retrieved, sitting below the strip's fully-loaded cost of goods at achievable clinic test volumes — [claim 14: unconfirmed] resolving negative against [assumption A2] and [assumption A3] together. If the clinic cannot make money running the test in-house, there is no buyer in this route, whatever the device measures.

Route B — License the hemolysis-detection module into an already-cleared analyzer

Ship the differentiator, not the form factor: the hemolysis-detect-and-suppress logic and the potassium-selective membrane chemistry, as an OEM add-on to an incumbent point-of-care analyzer that already has a cleared potassium channel and market presence — Piccolo Xpress (K200865) [claim 10: unconfirmed] or an i-STAT/StatSensor-family platform [claim 27: unconfirmed] — rather than competing on strip-and-meter form factor at all.

Requires: the hemolysis module validated as an add-on, reliably flagging a materially biased sample without an unworkable invalid-result rate [claim 22: unconfirmed], [claim 23: unconfirmed], [claim 40: unverified]; an FTO position on hemolysis/hemoglobin detection art specifically, the file's own highest-value single query and still unsearched [claim 25: unconfirmed]; and a partner among the named incumbents willing to integrate it [claim 27: unconfirmed].
Costs: regulatory scoping and bench-validation spend to qualify the module against the host device [assumption A10], in place of Route A's fleet/manufacturing capex — no strip-manufacturing scale-up and no clinic-channel build.
Killed by: bench data showing the hemolysis-suppression channel cannot reliably distinguish a materially biased sample from a clean one at the threshold that matters clinically — [claim 22: unconfirmed] resolving false. A module that misses lysis reports a falsely elevated result; one that over-triggers voids too many draws to be usable; either way there is nothing to license.

Route C — Launch the OTC/home-use lay-titration product as the primary route

Go directly to the version the candidate's own frontmatter calls the biggest commercial lever — at-home RAASi titration — rather than launching professional point-of-care first and treating home use as a later, second submission.

Requires: the professional-POC regulatory base [claim 1: verified], [claim 2: verified], [claim 3: verified], [claim 4: verified], [claim 5: verified], plus lay-comprehension and untrained-operator evidence this candidate does not yet carry; a real cleared home-use format analog exists on the same manufacturer's platform family [claim 6: verified], but it is a glucose/β-ketone meter, not a potassium or creatinine predicate. Patients would need to accept the fingerstick at all [claim 30: unconfirmed], and untrained lay users would need to obtain an adequate capillary drop without supervision, a harder version of the trained-operator question the file already flags as unresolved [claim 32: unverified].
Costs: a lay-comprehension/human-factors study package on top of the professional-track baseline [assumption A11], [assumption A7], [assumption A8].
Killed by: human-factors testing showing untrained home users cannot reliably obtain a valid capillary drop, or cannot correctly interpret a suppressed/invalid result without clinical supervision — [assumption A11] failing at the study stage, before a submission is even possible.

Route D — Contract with health systems on a monitoring-service basis, tied to RAASi/MRA continuation

Bypass the per-test CLFS margin question in Route A entirely: sell an in-visit monitoring service to health systems or HF/CKD disease-management programs, priced against the cost of RAASi/MRA discontinuation and its downstream consequences, rather than against a lab fee schedule.

Requires: a defensible, quantified link between in-visit potassium monitoring and reduced RAASi/MRA discontinuation — the file's own clinical-premise figures (RAASi cessation ~34.7%, MRA ~52.8% at one year following a hyperkalemia diagnosis) come from a search summary with no primary paper read [claim 20: unconfirmed]; and clinicians who actually act on an in-visit result rather than deferring to a confirmatory draw [claim 28: unconfirmed].
Costs: a health-system-level study or claims analysis establishing that link [assumption A12], on top of the same regulatory baseline as Route A [assumption A7], [assumption A8].
Killed by: no US health-system study or claims analysis being obtainable at an affordable cost and calendar to even test the association, or one that returns no measurable link between monitoring frequency and RAASi/MRA continuation — [assumption A12] failing to produce evidence in either direction. Without a measured link, there is no readmission- or continuation-avoidance budget line to sell into, only the clinical-premise claim as written.

Assumption register

Every assumption cited above, with what would settle it and who could run it. These are written back to the candidate as unverified claims 44-55 — an assumption that lives only in a business case is invisible to the Verifier.

#	Assumption	Falsifier	Owner
A1	The outpatient clinic itself, not a distributor, GPO, or health-system central lab, is the direct purchaser of the meter and strips	Revealed-behaviour twin: how comparable outpatient POC systems (glucose/ketone meters, INR meters, urinalysis analyzers) are actually procured in outpatient cardiology/nephrology clinics — direct clinic purchase vs. GPO contract vs. health-system central lab — from distributor sales-channel data or a purchasing-manager survey	Commercial / business development
A2	A net per-test strip price to the clinic can be set below the CLFS allowable for 84132 and 82565 combined, leaving room for manufacturer gross margin	A bill-of-materials cost roll-up from a contract manufacturer for a three-channel electrochemical strip (potassium ISE + enzymatic creatinine + hemolysis-detection channel) at stated annual volumes, set against the CLFS national limitation amounts for 84132 and 82565 once retrieved	Engineering + commercial
A3	The manufacturer earns positive gross margin on the strip at the price in A2	The same BOM roll-up as A2, expressed as margin against the assumed price	Engineering + finance
A4	The handheld meter can be priced or placed with clinics at a cost low enough, relative to strip volume, that it is not a barrier to adoption	Reference pricing or placement terms for comparable POC analyzers already in these clinics (Nova StatSensor, i-STAT, Piccolo Xpress) from public distributor price lists or GPO contract data	Commercial / business development
A5	A single outpatient HF or nephrology clinic that insources testing generates enough in-visit potassium/creatinine tests per year to make strip-and-meter economics work at clinic scale	Chart-review or clinic-operations data on the number of RAASi/MRA titration visits per active patient per year in a defined clinic panel, cross-referenced against the monitoring cadence in claim 21	Commercial / clinical operations
A6	A material share of clinics that insource testing choose this device over an already-cleared incumbent analyzer already in the room	Revealed-behaviour twin: purchase/fleet composition at named outpatient HF/nephrology clinics before and 12-24 months after the last comparable POC-analyte device launch, and the stated reason for adoption or non-adoption	Commercial / business development
A7	Calendar to first commercial dollar for the professional point-of-care launch is short enough to finance within a typical device-company runway	A regulatory consultant's written scoping opinion sizing a Dual 510(k)/CLIA Waiver by Application submission package once the FDA guidance document is read and the 862.1600/862.1225 special controls are scoped, benchmarked against comparable POC method-comparison study durations	Regulatory consultant
A8	Capital required to reach first commercial dollar for the professional point-of-care launch is within a typical device-company's raisable range	The same scoping opinion as A7, plus a contract-manufacturing capex quote for strip production scale-up	Regulatory consultant + finance
A9	The lag from a clinic's first purchase to its first paid CLFS claim on 84132/82565 is short enough that the clinic and the channel selling into it can finance the gap	Aged-receivables data from an operating outpatient lab drawing CLFS payment on comparable electrolyte/chemistry codes in a target state	Reimbursement analyst
A10	The hemolysis-detection-and-suppression module can be qualified as an add-on to an already-cleared point-of-care analyzer without triggering a new full 510(k) for the host device	A regulatory consultant's written scoping opinion on whether adding this module is a letter-to-file, a special 510(k), or a new submission for the host device, plus a bench-validation quote	Regulatory consultant + engineering
A11	The lay-comprehension and untrained-operator human-factors study package needed for an OTC home-use submission is affordable and completable within a launch budget, on top of the professional-track baseline	An FDA human-factors consultant's scoping opinion for an OTC IVD self-test submission, benchmarked against the human-factors package behind a comparable cleared home-use analyte meter (Nova Max Plus, K091547)	Regulatory consultant + human-factors specialist
A12	A US health-system-level study can establish, at an affordable cost and within a useful calendar, a measured association between in-visit potassium-monitoring frequency and RAASi/MRA discontinuation or its downstream cost	A CRO or health-economics-and-outcomes-research protocol scoping and quote against that specific endpoint	Clinical / HEOR

Where this case outruns the file

Every figure with no claim behind it, gathered as work items.

The purchaser of the device (A1) — no claim in the file names who buys the meter and strips, unlike idea-004's DME-supplier chain; this case had to introduce that identity as an assumption rather than read it off the candidate.
The entire strip and meter unit economics — net strip price (A2), manufacturer margin (A3), meter price or placement (A4) — nothing in the candidate speaks to any of the three, and together they are the entire device P&L.
Clinic-level test volume (A5) and this device's capture share among insourcing clinics (A6) — the file asserts an addressable-share range for insourcing overall [claim 18: unconfirmed] but nothing about volume per clinic or competitive capture once a clinic does insource.
Calendar and capital to first dollar (A7, A8) — the candidate explicitly declines to assert either figure, on the correct grounds that any number supplied would be invented [claim 26: unconfirmed].
The claims-cycle lag from purchase to first paid CLFS claim (A9) — no claim in the file speaks to working capital or days-to-payment.
Route B's regulatory/bench-validation spend to qualify an OEM module (A10), Route C's human-factors study cost (A11), and Route D's health-system study cost (A12) — none has any claim behind it; each is a distinct piece of primary work this case's routes depend on.
The composite dollar figure this document deliberately does not compute — every input row in the money model is either an unresolved connector primitive [claim 14: unconfirmed], [claim 16: unconfirmed], [claim 17: unconfirmed], [claim 18: unconfirmed], an unverified deck-surfaced proposition [claim 36: unverified], [claim 37: unverified], [claim 38: unverified], or a new assumption (A2-A6) — chaining them would manufacture a market size that market already refuses to produce.

Generated from knowledge-base/commercial/idea-010.md by engine/scripts/build_review.py on 2026-09-09. This page is a view — edit the source file and rebuild, never edit here.